Navigation Links
Neuralstem Fills Key Product Development Position


ROCKVILLE, Md., July 30 /PRNewswire-FirstCall/ -- Stem cell company Neuralstem, Inc. (Amex: CUR) announced that Dr. Thomas Hazel will be rejoining the company as Executive Vice President, Research. He will be working with Dr. Karl Johe, Neuralstem's Chairman and Chief Science Officer, to manage the company's upcoming clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease), and complete development of Neuralstem's small molecule neurogenesis compound targeted to treat depression.

(Logo: )

Dr. Hazel returns to Neuralstem after a four year stint as Chief Science Officer at Innovative BioSensors, in Maryland. Prior to that, Dr. Hazel worked with Dr. Johe at Neuralstem for four years to develop the company's techniques for isolating and growing human neural stem cells. Before Neuralstem in 1998, Dr. Hazel worked as a Senior Staff Scientist at the National Institute of Health, which he joined after receiving his Ph.D. in Genetics from the University of Illinois.

"Tom has the background to make a substantial contribution the day he arrives," observed Dr. Johe. "I expect this to accelerate our product development cycle."

"Tom's addition to our senior management team will increase its depth, expand the range of partners that we can work with worldwide, and speed up our progress to market," commented Neuralstem CEO, Richard Garr. "This is an important hire for us."

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company is currently targeting diseases and injuries of the spinal cord for its first human trials, including ALS and Paraplegia.

The company has also developed neurogenic and neuroprotective small molecule compounds targeted at treating depression. For further information, please visit

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended March 31, 2008.

SOURCE Neuralstem, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Responds to New StemCells, Inc. Lawsuit
2. Neuralstem Sues StemCells, Inc. Over New Patent
3. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
4. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
5. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
6. Neuralstem Shares Accepted for Trading on Amex(R)
7. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
8. Instrumentation Laboratory Announces Contract for Multi-Parameter Testing Products with Broadlane
9. Monsanto Announces Key Regulatory Approvals for Roundup Ready 2 Yield(TM) Soybeans; Product Remains on Track for 2009 Launch
10. Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry
11. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
Post Your Comments:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):